Matt Ronsheim Appointed President of Innoviva Specialty Therapeutics

Waltham, MA – January 4, 2024: Innoviva Specialty Therapeutics, a wholly-owned subsidiary of Innoviva, Inc. (NASDAQ: INVA) focused on developing and commercializing critical care and infectious disease therapies, announced today that Matt Ronsheim, PhD, has been appointed President.

“Innoviva Specialty Therapeutics has experienced significant growth over the past year resulting from excellent operational advancements that enabled the company to achieve important commercial and development milestones,” said Pavel Raifeld, Chief Executive Officer of Innoviva, Inc. “Matt’s proven leadership coupled with his extensive industry experience will be essential to the company’s  continued progress as a leader in critical care and infectious disease.”

Today’s announcement is part of a planned integration strategy as the company marks the first anniversary since its formation in January 2023.

Dr. Ronsheim is a seasoned pharmaceutical executive who brings more than 20 years of leadership experience to the position of President. He most recently served as the Chief Technical Officer at Innoviva Specialty Therapeutics and was the former President of Entasis Therapeutics, which was acquired by Innoviva, Inc. in 2022. Prior to his time at Entasis, he held leadership and executive positions in areas including CMC, pharmaceutical development, and commercialization at companies including Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals, and Forest Laboratories. Dr. Ronsheim’s industry contributions and leadership have contributed to delivering important therapies across several disease areas including anti-infectives, central nervous system disorders, and gastrointestinal conditions.

“I’m honored to take the role as President and lead a dynamic team of talented professionals with a common passion for developing and delivering innovative therapies that address urgent and often complex infectious disease and critical care conditions,” said Matt Ronsheim, PhD, President, Innoviva Specialty Therapeutics. “I remain focused on realizing the full potential of our marketed and pipeline assets and have great confidence in our company’s ability to further our mission to deliver our life-saving therapies to patients.”

About Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics’ products, through its affiliate, La Jolla Pharmaceutical Company, include GIAPREZA^® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA^® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva Specialty Therapeutics’ products, through its affiliate, Entasis Therapeutics Inc., include XACDURO^® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).

For more information about Innoviva Specialty Therapeutics, please visit here.

Forward Looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions.

These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA® and XACDURO® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (“COVID-19”); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy.

Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

Media Contacts:

David Patti
Corporate Communications
Innoviva, Inc.
(908) 421-5971
David.patti@inva.com

Argot Partners
(212) 600-1902
innoviva@argotpartners.com